secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001628280-23-007945
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem FY2022 revenue up 7% to record $109.9M, but adjusted EBITDA down 14%
-------------------------------------------------------------------------------

- Full year net revenue $109.9M (+7% YoY); Q4 revenue $28.8M (+9% YoY).
- Adjusted EBITDA $20.7M FY2022, down 14% YoY; Q4 adj. EBITDA $5.5M, down 16%.
- Net income for year less than $0.1M; Q4 diluted EPS $0.01.
- Guides FY2023 revenue growth 8-10% (~$118-121M); adj. EBITDA margin >19%.
- Launched wound care JV with Sanara Medtech; biomedical services contract ramp-up continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/0001628280-23-007945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/infu-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer